Search

Imetelstat

[erythropoietin]), but primary resistance to these agents is frequent - the median response duration is 18 to 24 months, with most responders (70%) relapsing due to loss of sensitivity of erythroid progenitors … [A263973] It is used to treat anemia in patients with myelodysplastic syndromes (MDS), a group of hematologic disorders characterized by ineffective hematopoiesis, peripheral cytopenia, abnormal marrow

Cyclacillin

A cyclohexylamido analog of penicillanic acid.

Vancomycin

29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis caused by

Fexinidazole

[A237555, L35940] It is currently marketed by Sanofi-Aventis.[L35940] … all-oral treatment for first and second stage HAT caused by _T. brucei gambiense_.

Rilpivirine

[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011.

Chlorphenesin

Anisotropine methylbromide

Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.

Pixantrone

It is similar in structure to anthracyclines such as mitoxantrone, but exerts fewer toxic effects on cardiac tissue. [2] The lower cardio-toxic effects of pixantrone may be explained, in part, by its redox … Pixantrone dimaleate, administered intravenously, was designed by Cell Therapeutics Incorporated as an alternative second line therapy in refractory or relapsed NHL.

Plicamycin

Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus.

Zopapogene imadenovec

Recurrent respiratory papillomatosis (RRP) is a rare, debilitating disease driven by chronic human papillomavirus (HPV) 6 or 11 infection and characterized by recurrent benign tumors in the respiratory … [L54071] It is the first and only therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with RRP, receiving full FDA approval on August 15, 2025.[L54081]